Moleculin Biotech (NASDAQ:MBRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research report sent to investors on Monday. The brokerage issued a sell rating on the stock. Moleculin Biotech Trading Up 3.6 % NASDAQ MBRX opened at $0.57 on Monday. Moleculin Biotech has a 1-year low of $0.34 and a 1-year high […]

Leave a Reply

Your email address will not be published.

Previous post EchoStar (NASDAQ:SATS) Receives New Coverage from Analysts at StockNews.com
Next post EMCORE (NASDAQ:EMKR) Earns Hold Rating from Analysts at StockNews.com